Vasculata 2018
St. Louis, MO
July 23 - 26, 2018
Supported in part by the: 
Vascular Biology
Newport, RI
October 14-18, 2018
Lymphatic Forum 2019
Austin, TX
May 31 - June 1, 2019
|
Your data privacy and security are important to NAVBO. To that end, we have updated our privacy policy to reflect recent privacy and security regulation implementations and changes.
Please review our policy as time permits so you have a complete understanding of the data we have, why we have it, and how we use it.
Part of the updates relate directly to the European Union's new General Data Protection Regulation (GDPR) that went into place May 25. The GDPR seeks to improve the transparency of data usage and give end users more control over their own data. We believe these changes are important and will be compliant with the GDPR regulations.
Contact NAVBO if you have any questions or to
change your communication preferences.
Please note, you can unsubscribe to this newsletter at anytime by clicking on the SafeUnsubscribe in the footer.
|
|
 |
|
|
Bring Vasculata to Your Institution!
|
|
If you can't come to Vasculata - have Vasculata come to you!
Bring the live streaming webcast of Vasculata to your institution
Have access to all five sessions:
Blood Vessel Development
ECM and Muscle in the Vessel Wall
Core Physiology
Cells of the Blood
The Vasculature in Disease
Participate in live Q&A with 29 speakers within the web cast
Find out more, go to -
And you can still register for the live presentation and go to St. Louis!
|
|
Nominate a Colleague for a NAVBO Award
|
Seeking nominations for the Judah Folkman and Earl P. Benditt Awards.
These are NAVBO's most prestigious honors and each one reading this knows of several colleagues that are deserving of one of these honors.
The
Earl P. Benditt Award recognizes an individual who has made an outstanding discovery or developed a concept that has been seminal to our understanding of vascular biology or pathology. More information is available here:
http://www.navbo.org/awards/earl-p-benditt-award
The
Judah Folkman Award in Vascular Biology is a mid-career award, and in recognition of the breadth of Dr. Folkman's interests and his many contributions to vascular biology is not limited to the field of angiogenesis, but encompasses the full range of original research in vascular biology. The recipient will have made a significant impact on the field through his/her original research accomplishments. Information can be found here:
http://www.navbo.org/awards/judah-folkman-award
The submission deadline has been extended to July 27. Please honor your colleagues by nominating them for one of these prestigious awards.
|
|
NAVBO Council Election Results
|
Thank you to all the members that voted!
President-Elect:
Ondine Cleaver, UT Southwestern Medical Center
Councilors:
Zorina Galis, NHLBI/NIH and
Kristy Red-Horse, Stanford University
A special thank you to all the candidates for your willingness to serve NAVBO!
|
Sign up now for our August 2 Webinar with Michael Dellinger
Our webinar attendees requested a webinar on Lymphatics, so please join us on August 2 at 1:00pm EDT for Dr. Dellinger's presentation,
"Lymphatic Vessels and Vanishing Bones: Animal Models of Lymphatic Anomalies with Bone Involvement." Dr. Dellinger is an Assistant Professor at UT Southwestern Medical Center.
The webinar is sponsored by the Lymphatic Malformation Institute and the Lymphangomatosis & Gorham's Disease Alliance.
To register for the webinar please go to
http://www.navbo.org/events/webinars/718-webinar082018
Please note: we will not be holding a July webinar
|
|
Bioinformatics at Vascular Biology 2018!!!
|
Watch the webinar and see how bioinformatics can enhance your research
(click on the slide to start the movie)
Attend Vascular Biology 2018 and register for this special session!
Bring your lap top and your favorite gene!!
|
MIT's Robert Langer offers encouraging tips for early-career scientists
Robert Langer, a member of the MIT faculty since 1977, has had a spectacular career by any measure: he holds an Institute Professorship at MIT, has more than 1,400 published articles and 1,300 patents to his credit, and has earned more than 220 major professional awards including the US National Medal of Science. These achievements, however, came after what he regards as an inauspicious start in convincing colleagues and research sponsors about the value of his ideas. In a
recent piece in PartneringInsight, Dr. Langer shares lessons gleaned from his early-career experience.
|
The Lab of Dr. Cynthia St. Hilaire
|
Welcome to our New Members:
Christina Camell, Yale University
Chi Hsu, University of Rochester Medical Center
Xinyan Lu, University of Pittsburgh
Karin Simons, LUMC
Laura Wisniewski, University College London
|
|
Recent Publications by NAVBO Members
|
| The Novel Pathogenesis of Retinopathy Mediated by Multiple RTK Signals is Uncovered in Newly Developed Mouse Model
EBioMedicine
Diabetic retinopathy (DR) is a major cause of vision impairment worldwide. We newly developed retinopathy mouse model (N-PRβ-KO) with conditional Pdgfrb gene deletion by Nestin promoter-driven Cre recombinase consistently reproduced through early non-proliferative to late proliferative DR pathologies. Read more Use of 4-phenylbutyrate to define therapeutic parameters for reducing intracerebral hemorrhage and myopathy in Col4a1 mutant mice
Disease Models and Mechanisms
Collagen type IV alpha 1 (COL4A1) and alpha 2 (COL4A2) form heterotrimers that constitute a major component of nearly all basement membranes. COL4A1 and COL4A2 mutations cause a multisystem disorder that includes variable cerebrovascular and skeletal muscle manifestations. Read more Diabetic Vascular Calcification Mediated by the Collagen Receptor Discoidin Domain Receptor 1 via the Phosphoinositide 3-Kinase/Akt/Runt-Related Transcription Factor 2 Signaling Axis
Arteriosclerosis, Thrombosis, and Vascular Biology
Objective - Vascular calcification is a common and severe complication in patients with atherosclerosis which is exacerbated by type 2 diabetes mellitus. Read more Endothelial siRNA delivery in nonhuman primates using ionizable low-molecular weight polymeric nanoparticles
Science Advances
Dysfunctional endothelial cells contribute to the pathophysiology of many diseases, including vascular disease, stroke, hypertension, atherosclerosis, organ failure, diabetes, retinopathy, and cancer. Read more |
|
Medicine explored in its social context
The American Association of Medical Colleges has announced the program for its annual meeting, "
Learn Serve Lead 2018
," scheduled for early November in Austin, Texas. The meeting features an installment of the Voices of Medicine and Society series, including sessions that closely examine the current practice of medicine from a patient-centered viewpoint. Diverse stakeholders-medical school deans, hospital CEOs, university and hospital administrators, faculty physicians, scientists, researchers, physician residents, and students-are invited to think about ways that academic medicine can address its shortcomings and solve challenges that reach beyond clinical care.
Heightened risk for hypertension in African Americans
Data from the ongoing, prospective Coronary Artery Risk Development in Young Adults (CARDIA) study, initiated in 1985, reveal that African Americans face up to a 2-fold higher risk for hypertension compared to whites, regardless of their blood pressure levels in young adulthood. The recent report from Thomas et al. in the
Journal of the American Heart Association
noted that >75% of African Americans, male and female, are likely to develop hypertension (defined by the revised and
controversial 2017 AHA standards
) by age 55, while <55% of white men and 40% of white women were at similar risk. Body weight and diet were implicated as contributing factors, irrespective of race or gender.
Advances in non-viral genome targeting to reprogram cell function
Roth and colleagues at the multi-institutional Innovative Genomics Institute
report in Nature
novel methods to efficiently modify genes in cells of the immune system. The findings raise the intriguing prospect of new approaches to treat diseases, including cancer, infections like H.I.V., and autoimmune conditions, where defined and limited genetic alterations may produce therapeutic benefit. Existing virus-dependent methods of engineering lymphocytes for immunotherapy are limited by technical and temporal obstacles; these may be overcome with the new technique, by which both CRISPR-based gene editing tools and new genetic material are introduced into target cells subjected to electrical stimuli.
|
|
|
